2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
生物活性
Description
In Vivo
In Vitro
化合物的使用
Kinase Assay
Cell Assay
Animal Administration
参考文献
Tofacitinib (trade name Xeljanz, Formerly tasocitinib, CP-690550) is a drug discovered and developed by Pfizer. It is currently approved For the treatment of rheumatoid arthritis (RA) in the United States and is being studied For treatment of psoriasis, inflammatory bowel disease, and other immunological diseases, as well as For the prevention of organ transplant rejection.For the detailed information of Tofacitinib (CP-690550) Citrate, the solubility of Tofacitinib (CP-690550) Citrate in water, the solubility of Tofacitinib (CP-690550) Citrate in DMSO, the solubility of Tofacitinib (CP-690550) Citrate in PBS buffer, the animal experiment (test) of Tofacitinib (CP-690550) Citrate, the cell expriment (test) of Tofacitinib (CP-690550) Citrate, the in vivo, in vitro and clinical trial test of Tofacitinib (CP-690550) Citrate, the EC50, IC50,and Affinity of Tofacitinib (CP-690550) Citrate, Please contact DC Chemicals.
